Skip to main content
Caplight Logo









VacV Biotherapeutics

VacV Biotherapeutics

Private
HelsinkiHealthcare & Life Scienceshttps://vacvbtx.com/

Last Round

Grant

Aug 28, 2024

Total Funding Raised

$3.62M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

VacV Biotherapeutics is a biotechnology company developing a novel cancer immunotherapy platform based on its proprietary oncolytic virus technology to treat solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

oncolytic virus therapyoncolytic Vaccinia viruscancer-killing viruscancer immunotherapyimmuno-oncologyvirotherapysolid tumor therapyengineered virus therapysystemic deliverypre-clinical biotechglioblastomaintravenous deliverypancreatic cancerDIPGacademic spin-out

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

VacV Biotherapeutics Comparables

Compare VacV Biotherapeutics with similar companies based on industry and business-model similarity.

VacV Biotherapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Omios Biologics
86%
ReIGNITE Therapeutics
83%
KaliVir Immunotherapeutics
81%

VacV Biotherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantAug 28, 2024
SeedOct 26, 2022

Key People

Founding team and executive leadership

Yidan Zhang

Global CEO

Executive Team

VacV Biotherapeutics Investors

Notable investors and investment history

VacV Biotherapeutics investors
InvestorRounds
Innovate UKGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 19, 2026

    Monthly visitors increased 91% MoM.

  • Jul 6, 2025

    Monthly visitors increased 371% MoM, from 51 to 240.

VacV Biotherapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

VacV Biotherapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about VacV Biotherapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersHelsinki
Employee Range10
Year Founded2021
Last FundingAug 28, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?